Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISINE vs OPCON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.
Relief of ocular redness due to minor irritations,Off-label: symptomatic treatment of allergic conjunctivitis
Management of diabetes insipidus,Control of polyuria and polydipsia following traumatic or surgical head injury,Treatment of nocturnal enuresis in children (off-label),Treatment of hemophilia A and von Willebrand's disease (type I) to increase factor VIII and von Willebrand factor levels (off-label)
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
The terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing; half-life is prolonged in renal impairment.
Not systemically absorbed; no significant metabolism occurs in the eye.
Primarily metabolized in the liver by disulfide bond reduction and peptide cleavage. Not significantly metabolized by cytochrome P450 enzymes.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Renal elimination of unchanged drug accounts for approximately 65-70% of the administered dose; biliary/fecal excretion accounts for 20-25% following hepatic metabolism.
Approximately 80% bound to plasma proteins, primarily albumin
Approximately 80-85% bound to serum albumin and alpha-1-acid glycoprotein.
Not clinically significant for topical ophthalmic use; systemic Vd estimated at 0.5-1 L/kg based on IV data
Vd is approximately 1.5-2.0 L/kg, indicating extensive distribution into total body water and tissues.
Ocular: negligible systemic bioavailability (<1% from topical dose); oral not applicable
Oral bioavailability is 85-90% due to minimal first-pass metabolism; intramuscular bioavailability is nearly 100%.
No dose adjustment required; systemic absorption is minimal.
No dosage adjustment required for renal impairment.
No dose adjustment required; systemic absorption is minimal.
Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Use with caution; consider dose reduction by 50%.
Children 6 years and older: 1 drop in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily. Safety and efficacy in children under 6 years not established.
IV: 0.02-0.04 mg/kg/dose every 5-10 minutes as needed; max single dose: 0.1 mg/kg; max total dose: 2 mg.
No specific dose adjustment, but use with caution due to increased risk of systemic effects (e.g., hypertension, cardiac arrhythmias) and potential for angle-closure glaucoma.
Initiate at lower end of dosing range (e.g., 1-2 mg IV); titrate carefully due to increased sensitivity.
None
WARNING: SEVERE HYPONATREMIA. Desmopressin can cause hyponatremia which may be life-threatening if severe and untreated. Risk is increased in patients with conditions predisposing to hyponatremia or those receiving certain medications. Monitor serum sodium levels, especially in the elderly, children, and patients with increased intracranial pressure.
Do not use in patients with narrow-angle glaucoma; overuse may cause rebound hyperemia; avoid in children under 6 years; discontinue if eye pain or vision changes occur.
Risk of severe hyponatremia and seizures; monitor fluid intake and serum sodium; use with caution in patients with fluid and electrolyte imbalances, renal impairment, cystic fibrosis, coronary artery disease, hypertension, and in the elderly; may increase blood pressure; avoid in patients with nephrotic syndrome or nephropathy; use with caution in patients receiving drugs that increase diuresis or thirst.
Hypersensitivity to tetrahydrozoline or any component; narrow-angle glaucoma; concurrent use with MAO inhibitors
Hypersensitivity to desmopressin or any component; moderate to severe renal impairment (e GFR < 50 m L/min/1.73 m²); hyponatremia or propensity for hyponatremia; primary nocturnal enuresis in patients with uncontrolled hypertension or history of electrolyte disturbances; von Willebrand's disease type IIB (off-label use)
No known food interactions. Avoid alcohol as it may exacerbate eye redness or irritation.
No specific food interactions. Avoid alcohol as it may increase dizziness or drowsiness.
No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. Second and third trimesters: no specific risks identified. However, avoid prolonged use due to potential vasoconstrictive effects.
Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterine hypertonus.
Negligible systemic absorption with topical ocular use; M/P ratio not determined. Excretion into breast milk unlikely. Considered compatible with breastfeeding; use caution with excessive or prolonged use.
Excreted in human milk in low concentrations; M/P ratio approximately 0.6. Use with caution due to potential for adverse effects in nursing infants.
No dose adjustments necessary for pregnancy as systemic absorption is negligible. Standard dosing (1-2 drops every 8-12 hours) applies. Avoid overuse due to potential for rebound congestion or systemic effects.
No standard dose adjustment recommended; however, increased clearance in pregnancy may require higher doses to achieve therapeutic effect. Titrate based on clinical response and maternal-fetal monitoring.
Visine (tetrahydrozoline) is a topical ocular decongestant; prolonged use (>72 hours) can cause rebound hyperemia and conjunctivitis medicamentosa. Avoid in patients with narrow-angle glaucoma, cardiovascular disease, or hypertension. Do not use in children under 2 years without medical advice.
OPCON is a brand name for oxymetazoline, an α-adrenergic agonist used topically for nasal congestion. Avoid use beyond 3 days to prevent rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma and after transsphenoidal hypophysectomy. Monitor for rebound congestion.
Do not use Visine for more than 3 days to avoid rebound redness.,Remove contact lenses before instilling drops and wait at least 15 minutes before reinserting.,Do not share the bottle to prevent infection.,Avoid touching the dropper tip to any surface or the eye.,If eye pain, vision changes, or persistent redness occur, discontinue use and consult a doctor.
Do not use for more than 3 days to avoid worsening congestion.,Spray once into each nostril twice daily as needed.,Avoid contact with eyes; rinse with water if contact occurs.,Do not share the bottle to prevent infection.,Consult a doctor if symptoms persist beyond 3 days.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISINE vs OPCON, answered by our medical review team.
VISINE is a Ophthalmic Decongestant that works by Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.. OPCON is a Ophthalmic Decongestant (Vasoconstrictor) that works by Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISINE and OPCON depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISINE is: 1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.. The standard adult dose of OPCON is: IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISINE and OPCON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISINE is classified as Category C. No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. S. OPCON is classified as Category C. Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterin. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.